Abeona Therapeutics (ABEO) Non-Current Assets (2010 - 2026)

Abeona Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $15.5 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 37.94% year-over-year to $15.5 million in Q1 2026; TTM through Mar 2026 was $59.1 million, a 67.19% increase from a year earlier, with the FY2025 full-year figure at $14.7 million, up 81.53% from the prior year.
• Non-Current Assets rose to $15.5 million in Q1 2026 per ABEO's latest filing, from $14.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $16.0 million in Q1 2022 and bottomed at $7.9 million in Q3 2024.
• The 5-year median for Non-Current Assets is $11.1 million (2022), against an average of $11.4 million.
• Across the five-year window, Non-Current Assets tumbled 74.05% in 2022 and surged 88.59% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $11.1 million in 2022, then slipped by 25.64% to $8.3 million in 2023, then declined by 2.26% to $8.1 million in 2024, then jumped by 81.53% to $14.7 million in 2025, then rose by 5.76% to $15.5 million in 2026.
• Per Business Quant, the three latest ABEO Non-Current Assets figures stand at $15.5 million (Q1 2026), $14.7 million (Q4 2025), and $15.0 million (Q3 2025).